FDA Grants Mirvetuximab Full Approval for Ovarian Cancer FDA Grants Mirvetuximab Full Approval for Ovarian Cancer
Mirvetuximab soravtansine-gynx (Elahere) is approved for patients with folate receptor –alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 25, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
Can You Help Prevent Ovarian Cancer? Can You Help Prevent Ovarian Cancer?
The doctors behind Outsmart Ovarian Cancer say “interception” begins with the fallopian tube, not the ovary as traditionally thought.WebMD (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 22, 2023 Category: Surgery Tags: Hematology-Oncology Expert Interview Source Type: news
Mesothelioma Immunotherapy Receives Orphan Drug Designation
A novel therapy for mesothelioma has been given orphan drug designation by the U.S. Food and Drug Administration.
Avenge Bio, a biotechnology company working on a new treatment platform for immunotherapy, announced it was granted the designation for its drug AVB-001 in June. It is currently enrolling patients in ongoing phase 1 and phase 2 clinical trials for the treatment of advanced ovarian cancer, primary peritoneal mesothelioma and fallopian tube cancer.
AVB-001 is a new treatment being developed by Avenge Bio using its LOCOcyte immunotherapy platform to treat solid tumors. It’s a first-in-human, si...
Source: Asbestos and Mesothelioma News - August 9, 2023 Category: Environmental Health Authors: Lynette Zilio Tags: Clinical Trials/Research/Emerging Treatments Source Type: news
Janssen Marks First Approval Worldwide for AKEEGA ® (Niraparib and Abiraterone Acetate Dual Action Tablet) with EC Authorization for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations
BEERSE, Belgium, 21 April 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) has granted marketing authorisation for AKEEGA® (niraparib and abiraterone acetate [AA]), in the form of a dual action tablet (DAT), given with prednisone or prednisolone, for the treatment of adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.2Prostate cancer is the most common cancer in men in Europe, and the sixth-highest cause of cancer-related death worldwide.1...
Source: Johnson and Johnson - April 21, 2023 Category: Pharmaceuticals Tags: Innovation Source Type: news
Patients Needed for New Mesothelioma Clinical Trial
A new investigational drug for mesothelioma can now begin human trials after it was granted fast-track designation by the U.S. Food and Drug Administration last week. The novel treatment, SnyKIR-110, is a T-cell therapy designed to treat patients with mesothelioma, cholangiocarcinoma (bile duct cancer) and ovarian cancer.
“We are thrilled to receive fast-track designation from the FDA,” said Dr. Bryan Kim, co-founder and CEO of Verismo Therapeutics. “This designation is an important milestone in our efforts to bring this potentially life-saving drug to patients who are in need of new treatment option...
Source: Asbestos and Mesothelioma News - April 19, 2023 Category: Environmental Health Authors: Fran Mannino Tags: Clinical Trials/Research/Emerging Treatments Mesothelioma Source Type: news
The Fight for Medically Assisted Suicide Across State Lines
MONTPELIER, Vt. — Lynda Bluestein has terminal cancer and knows she’ll likely die soon, but until Tuesday, she didn’t know if she’d be able to choose how or when and whether her family, friends and dog would be with her when the time comes.
The 75-year-old from Bridgeport, Connecticut, reached a settlement with the state of Vermont that will allow her to be the first non-resident to take advantage of its decade-old law that allows people who are terminally ill to end their own lives, provided she complies with other aspects of the law.
“I was so relieved to hear of the settlement of my case th...
Source: TIME: Health - March 14, 2023 Category: Consumer Health News Authors: Lisa Rathke/AP Tags: Uncategorized Health Care healthscienceclimate wire Source Type: news
Women at high risk of ovarian cancer should consider fallopian tube removal, experts say
Experts are drawing attention to the fallopian tubes' role in many cases of ovarian cancer and say more women should consider having them removed to cut their cancer risk. (Source: CNN.com - Health)
Source: CNN.com - Health - March 3, 2023 Category: Consumer Health News Source Type: news
Janssen Submits New Drug Application to the U.S. Food and Drug Administration Seeking Approval of Niraparib and Abiraterone Acetate Dual-Action Tablet, Plus Prednisone, as a First-Line Targeted Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with BRCA Gene Mutations
RARITAN, N.J., February 28, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of niraparib in combination with abiraterone acetate, in the form of a dual-action tablet (DAT), plus prednisone, for the treatment of patients with BRCA-positive metastatic castration-resistant prostate cancer (mCRPC). If approved, this will be the first DAT formulation available in the U.S. to patients with mCRPC with BRCA mutations, which are a type of homologous recombination repair (HRR) gene alt...
Source: Johnson and Johnson - March 1, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Receives Positive CHMP Opinion for AKEEGA ® (Niraparib and Abiraterone Acetate Dual Action Tablet) Plus Prednisone or Prednisolone for the Treatment of Adult Patients with BRCA1/2 Gene-Mutated Metastatic Castration Resistant Prostate Cancer
BEERSE, Belgium, 24 February 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorisation for AKEEGA® (niraparib and AA), in the form of a DAT, given with P or prednisolone, for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.[1]Niraparib is a highly selective poly adenosine diphosphate-ribose polymerase (PARP) inhibi...
Source: Johnson and Johnson - February 27, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents Updated Data Demonstrating Improved Outcomes from the Use of Niraparib in Combination with Abiraterone Acetate Plus Prednisone as a First-Line Therapy in Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
SAN FRANCISCO, February 16, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 MAGNITUDE study evaluating the investigational use of niraparib, a highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) with or without specific homologous recombination repair (HRR) gene alterations, including BRCA mutations. Results will be featured today in a Rapid Abstract Session (Abstract #170) at the American Society of Clinica...
Source: Johnson and Johnson - February 16, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Consider Fallopian Tube Removal to Avoid Ovarian Cancer
The new advice replaces the decades old focus on symptom awareness and early detection of ovarian cancer through screening. (Source: WebMD Health)
Source: WebMD Health - February 10, 2023 Category: Consumer Health News Source Type: news
Why It ’ s So Hard to Have Your Fertility Tested
Patients often say the same thing in appointments with Dr. Abey Eapen, an infertility specialist at UT Southwestern Medical Center: “I never learned about this in my high school.”
For many couples, having a baby is far more difficult than it was made out to be in sex ed. While many women in heterosexual couples get pregnant within a few months of trying, studies suggest up to 15% of couples are unable to conceive after a year of having unprotected sex. That means they meet the clinical definition of infertility: not conceiving within a year if the woman is younger than 35, or within six months if she’s 35...
Source: TIME: Health - February 9, 2023 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthscienceclimate medicine Wellbeing Source Type: news
Renewed Calls for Fallopian Tube Removal to Avoid Ovarian Cancer Renewed Calls for Fallopian Tube Removal to Avoid Ovarian Cancer
Renewed calls for all women to consider having their fallopian tubes removed once they have finished with childbearing come from the Ovarian Cancer Research Alliance.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 7, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Faking a Cancer Dx? Fallopian Tube Removal; Trodelvy's New Breast Cancer Indication
(MedPage Today) -- A 19-year-old Iowa woman has been arrested after being accused of faking diagnoses of leukemia and pancreatic cancer in order to collect more than $37,000 in online donations. (CBS News)
The Ovarian Cancer Research Alliance... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 3, 2023 Category: Hematology Source Type: news
Fallopian tube removal advised for more women to prevent ovarian cancer
Some researchers are recommending that many women undergoing gynecologic surgery consider having their fallopian tubes removed to lower risk for ovarian cancer. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - February 2, 2023 Category: Consumer Health News Authors: Teddy Amenabar Source Type: news
